Charts Week Month
Heat map Market Overview
Sentiment Sectors ETFs
Earnings News Earnings Movers The Drift Pivots
The Big Picture Breakouts Full Earnings News
Investor Services

Earnings are the driver of stock prices and the right earnings information can help longer-term investors significantly outperform the overall stock market.

The Whisper Report ® A look at upcoming earnings from both a top-down and bottom-up basis. Grades Stocks with A+ Earnings Whisper Grades Have Significantly Outperformed the Stock Market. Call Summaries Conference call summaries. AI Call Analysis AI Conference call analysis. Earnings Daily earnings results. Guidance Daily earnings guidance from companies. Reactions Earnings Screener Short Interest Report When the short trade becomes crowded.
Trader Service

Short-term earnings trading tools built around expectations, sentiment, quantitative studies, volatility, and post-earnings drift.

Trading Strategy The current strategy based on a broad market analysis and data. Earnings Whisper Plays Combining research, sentiment, quantitative studies, and technical analysis for short-term trades. Scores Identifying the likely Earnings Announcement Premium. Power Ratings Earnings with enough power for a short-term Post-Earnings Announcement Drift. Whisperings ^TM Whisperings are comments from analysts about upcoming earnings releases. AI Call Rankings Find which companies had the strongest or weakest conference calls. Option Trades Volatility Options Activity Unusual options activity around earnings. Setups Unusual options activity around earnings. Reversals Unusual options activity around earnings. Spikes Unusual options activity around earnings.
Dashboard

HRMY Harmony Biosciences Holdings, Inc.

NASDAQ

$38.12

Harmony Biosciences Holdings, Inc. (HRMY) Earnings News

Earnings press releases and Earnings Whispers previews for Harmony Biosciences Holdings, Inc. (HRMY), newest first.

Tuesday August 4, 2026 7:30 AM ET

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

Tuesday July 21, 2026 8:05 AM ET

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

Thursday July 16, 2026 8:30 AM ET

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Thursday May 7, 2026 7:30 AM ET

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

Thursday April 23, 2026 8:05 AM ET

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

Tuesday April 14, 2026 8:05 AM ET

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

Tuesday February 24, 2026 7:30 AM ET

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion